PhD Scientific Days 2022

Pharmaceutical Sciences II. (Poster discussion will take place in the Aula during the Coffee Break)

Combination of ulinastatin and somatostatin reduces complication rates in acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials

Előadó neve

Dr. Horváth, István László

Előadó munkahelye

University Pharmacy Department of Pharmacy Administration

Előadó telefonszáma

+36206632947

Előadó e-mail címe

horvath.istvan@pharma.semmelweis-univ.hu

Az előadás címe

Combination of ulinastatin and somatostatin reduces complication rates in acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials

Szerző(k) neve és munkahelye

István László Horváth1,2, Stefania Bunduc1,4,6,7, Péter Fehérvári1,8, Szilárd Váncsa1,4, Rita Nagy1,4, Gantsetseg Garmaa1,9, Dénes Kleiner1,2, Péter Hegyi1,3,4,5, Bálint Erőss1,3,4,5, Dezső Csupor1,3,10
Affiliations
1 Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Üllői út 26, Hungary
2 University Pharmacy Department of Pharmacy Administration, 1092 Budapest, Hőgyes Endre utca 7-9.
3 Institute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Szigeti út 12, Hungary
4 Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, 1085 Budapest, Baross út 22-24, Hungary
5 János Szentágothai Research Center, University of Pécs, 7624 Pécs, Szigeti út 12, Hungary
6 Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Dionisie Lupu street 37, Romania
7 Fundeni Clinical Institute, 022328 Bucharest, Fundeni street 258, Romania
8. University of Veterinary Medicine, Budapest Department of Biomathematics and Informatics, 1078 Budapest, István utca 2
9. Institute of Translational Medicine, Semmelweis University, 1085 Budapest, Üllői út 26, Hungary
10. Institute of Clinical Pharmacy, University of Szeged, 6725 Szeged, Szikra utca 8, Hungary

Bemutatás módja

Poszter

Szekció

Pharmaceutical Sciences II. (Poster discussion will take place in the Aula during the Coffee Break)

Language of the presentation

English

Preferred session

Pharmaceutical Sciences

Összefoglaló szövege

Introduction
Currently, there is no specific pharmaceutical agent for treating acute pancreatitis (AP). Somatostatin and its analogues have been used to prevent the autolysis of the pancreas in AP; however, their effectiveness has not been confirmed.
Aim
This investigation aimed to examine the safety and efficacy of ulinastatin, a protease inhibitor combined with somatostatin analogues in the treatment of AP.
Materials and methods
We conducted a systematic database search in PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science to identify randomized controlled trials in which the efficacy of ulinastatin in combination with somatostatin analogue was compared to somatostatin analogue alone in patients with AP. The meta-analysis is reported according to PRISMA guidelines. For statistical analysis the random effect model were used; odds ratio (OR) and mean differences (MD) with confidence interval (CI) were calculated. I2 value and Χ2 test evaluated statistical heterogeneity.
Results
In total of 60 articles, comprising 1037 patients were included in the meta-analysis. Disease severity and posology for treatment in each group varied across the studies. The combination therapy significantly increased the symptom reduction rate [OR 3.51; 95%CI 2.30-5.37; I2=0%], and decreased length of hospital stay [9.43 days; 95%CI (-12.55)-(-6.31); I2=97%]. Furthermore, it reduced the complications rate for acute respiratory distress syndrome [OR 0.27; 95%CI 0.13-0.60; I2=28%]; acute kidney injury [OR 0.29; 95%CI 0.09.-0.97; I2=49%] and multiple organ dysfunction syndrome [OR 0.39; 95%CI 0.20-0.75; I2=0]. The decrease in mortality was not statistically significant [OR 0.55; 95%CI 0.29-1.07; I2=0%].
Conclusions
The combination therapy decreased complication rates (of MODS, ARDS, AKI). Symptoms were relieved threefold with the combination therapy compared to somatostatin alone and resulted in a significantly shortened length of hospital stay. Further RCTs of greater sample sizes would better evaluate the effect on major complications rates and mortality of this combination therapy.

University and Doctoral School

Semmelweis University, Doctoral School of Pharmaceutical Sciences

Supervisor

Dezső Csupor Dr.

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6825

Start

10:35

End

10:40

Authors (legacy)

István László Horváth1,2, Stefania Bunduc1,4,6,7, Péter Fehérvári1,8, Szilárd Váncsa1,4, Rita Nagy1,4, Gantsetseg Garmaa1,9, Dénes Kleiner1,2, Péter Hegyi1,3,4,5, Bálint Erőss1,3,4,5, Dezső Csupor1,3,10
Affiliations
1 Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Üllői út 26, Hungary
2 University Pharmacy Department of Pharmacy Administration, 1092 Budapest, Hőgyes Endre utca 7-9.
3 Institute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Szigeti út 12, Hungary
4 Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, 1085 Budapest, Baross út 22-24, Hungary
5 János Szentágothai Research Center, University of Pécs, 7624 Pécs, Szigeti út 12, Hungary
6 Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Dionisie Lupu street 37, Romania
7 Fundeni Clinical Institute, 022328 Bucharest, Fundeni street 258, Romania
8. University of Veterinary Medicine, Budapest Department of Biomathematics and Informatics, 1078 Budapest, István utca 2
9. Institute of Translational Medicine, Semmelweis University, 1085 Budapest, Üllői út 26, Hungary
10. Institute of Clinical Pharmacy, University of Szeged, 6725 Szeged, Szikra utca 8, Hungary